Author:
Schnitzler C. M.,Wing J. R.,Raal F. J.,van der Merwe M. T.,Mesquita J. M.,Gear K. A.,Robson H. J.,Shires R.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism
Reference39 articles.
1. Meunier PJ, Boivin G. Fluoride salts for vertebral osteoporosis: the benefit-to-risk ratio depends on the cumulative dose reaching bone. Osteoporos Int 1993; 3(Suppl 1):S211–4.
2. Kleerekoper M. Mendlovic B. Sodium fluoride therapy of postmenopausal osteoporosis. Endocr Rev 1993; 14:312–23.
3. Mamelle N, Meunier PJ, Dusan R, Gillaume M, Martin JL, Gaucher A, et al. Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 1988;2:361–5.
4. Pak CYC, Sakhaee K, Piziak V, Petersen RD, Breslau NA, Boyd P, et al. Slow-release sodium fluoride in the management of postmenopausal osteoporosis. Ann Intern Med 1994; 120:625–32.
5. Nagant de Deuxchaisnes C, de Vogelaer JP, Depresseux G, Malghem J, Maldague B. Treatment of the vertebral crush fracture syndrome with enteric-coated sodium fluoride tablets and calcium supplements. J Bone Miner Res 1990;5(Suppl 1):S5–26.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献